Measurement of the Folate Receptor in Blood
NCT00838747 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 7
Last updated 2016-05-26
Summary
The folate receptor (FR) is a cell marker that is over expressed on the cell surface of certain cancers, this occurs most frequently in ovarian cancers. Some normal tissues also express the FR, however in these normal tissues the FR is usually located on the tissue surface that is inaccessible to circulating drugs. As such, drugs which target the FR may potentially be used to achieve anti-tumour efficacy whilst reducing toxicity to normal tissues. Therefore the ability to measure FR levels from different cancer types may help to select patients who are most likely to benefit from treatment with FR targeted therapies. One such drug BGC 945 is currently being tested in preclinical study at The Institute of Cancer Research
Conditions
- Healthy
Sponsors & Collaborators
-
Royal Marsden NHS Foundation Trust
lead OTHER
Principal Investigators
-
Stan Kaye, Professor · Royal Marsden NHS Foundation Trust
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-09-30
- Primary Completion
- 2011-01-31
- Completion
- 2011-07-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Collection of Blood From Patients With Cancer
NCT00034216 ·Status: RECRUITING
-
Intraoperative Detection of Residual BCC by Fast Raman
NCT03482622 ·Status: UNKNOWN
-
Exploratory Study of Molecular Characterization in Patients With Metastatic Germ Cell Tumours Refractory/Resistant to Platinum Treatment
NCT03980587 ·Status: UNKNOWN
-
Measuring Cell-Free DNA (cfDNA) Levels in People With Follicular Lymphoma
NCT04468841 ·Status: RECRUITING ·Phase: PHASE1
-
Novel Prognostic Markers in Renal Cancer
NCT01002937 ·Status: COMPLETED
-
Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or Pancreatic Cancer
NCT00898781 ·Status: TERMINATED
-
Project CADENCE (CAncer Detected Early caN be CurEd)
NCT05633342 ·Status: UNKNOWN
-
Identification of Marker of Primary or Acquired Resistance to Anti Tumorous Treatment
NCT02105168 ·Status: UNKNOWN ·Phase: NA
-
Research Into Biomarkers Predictive of Survival and Response to Cancer Treatment
NCT06851975 ·Status: RECRUITING ·Phase: NA
-
Blood Cell RNA-Based Cancer Detection
NCT05839834 ·Status: RECRUITING
-
BRCA1 Haploinsufficiency and Gene Expression
NCT00597987 ·Status: COMPLETED
-
mFOCUS (Multilevel FOllow-up of Cancer Screening)
NCT03979495 ·Status: COMPLETED ·Phase: NA
-
Detection of Tumor DNA in Blood Samples From Cancer Patients
NCT02288754 ·Status: UNKNOWN
-
Tumor-Derived FGF19
NCT06068257 ·Status: RECRUITING
-
Analysis of Expression of Specific Markers in Hepatocellular Carcinoma
NCT00858000 ·Status: COMPLETED
-
RCM to Diagnose BCC - Reflectance Confocal Microscopy to Diagnose Basal Cell Carcinoma
NCT03331874 ·Status: COMPLETED
-
S8947-9800-9911-0016A Vitamin D Insufficiency in Determining Prognosis in Patients With Newly Diagnosed Follicular Lymphoma
NCT01131221 ·Status: COMPLETED
-
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
NCT05697198 ·Status: COMPLETED
-
Characterization of Human Cancers by Molecular Profiling of Patient Biospecimens
NCT02749838 ·Status: UNKNOWN
-
DNA Analysis in Influencing Response to Rituximab in Samples From Patients With Follicular Lymphoma Treated on ECOG-E4402
NCT01406782 ·Status: COMPLETED
-
Detection of Melanoma Markers in Lymph Nodes or Peripheral Blood of Patients With Melanoma
NCT00004153 ·Status: COMPLETED ·Phase: NA
-
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT04009148 ·Status: ACTIVE_NOT_RECRUITING
-
Detection of Germline and Somatic Pathogenic Variants in Patients With de Novo Metastatic Breast Cancer
NCT05758948 ·Status: UNKNOWN
-
The Identification of Novel Prognostic Markers in Melanoma
NCT01002560 ·Status: UNKNOWN
-
Studying Tumor Tissue Samples From Patients With Melanoma Who Have Undergone Sentinel Lymph Node Biopsy
NCT00897481 ·Status: UNKNOWN